The U.S. Food and Drug Administration announced the Global Reliance Disclosure Program on Tuesday to share minimally redacted approval packages with companies for foreign regulators. The program aims to accelerate patient access to medicines worldwide.

The Global Reliance Disclosure Program launched on Oct. 30 with a PEPFAR tentative approval for lenacapavir, a drug for HIV prevention and treatment. The program is currently available to PEPFAR tentative approvals but excludes tentatively approved abbreviated new drug application products.

Applicants must request to participate in the Global Reliance Disclosure Program within 10 calendar days of approval. Applicants must confirm the package is being submitted to a foreign regulatory authority.

The FDA intends to expand the Global Reliance Disclosure Program in January 2027 to all novel drug and biologics, specifically New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. The FDA intends to launch a pathway in early 2027 to expedite requests for minimally redacted action packages for already approved and licensed drugs and biologics.

Why It Matters

The initiative involves an 11-year span of events from 2016 to 2027. As of 2023, PEPFAR has saved over 25 million lives, primarily in sub-Saharan Africa.